Introduction {#s0005}
============

Oral squamous cell carcinoma (OSCC) is a common malignant tumor of the oral cavity and has a high incidence with poor prognosis ([@bb0010], [@bb0005]). In India, OSCC is one of the major causes of cancer-related deaths. It is predominant in Indian males ([@bb0015], [@bb0020]). OSCC is a multistep progression which is influenced by several environmental factors, such as tobacco chewing, smoking and alcohol consumption and alteration in genes, such as genetic tumor suppressor genes and oncogenes ([@bb0025], [@bb0030]). Several studies have observed that the common polymorphisms in angiogenesis, inflammation and thrombosis-related genes, are associated with increased risk for oral cancer ([@bb0015], [@bb0025], [@bb0020], [@bb0040], [@bb0035]). One such factor, related with both thrombosis and malignancies, is interleukin-6 (IL-6) ([@bb0045], [@bb0050], [@bb0060], [@bb0055]). IL-6, also known as B cell differentiation factor, is an immune regulatory cytokine, involved in the regulation of various cellular functions (angiogenesis, apoptosis, proliferation, differentiation and regulation of immune response) ([@bb0065]). IL-6 may also have an essential role in the growth and differentiation of malignant tumors ([@bb0070], [@bb0075]).

IL-6 is a multifunctional cytokine of Th2 type which has both, pro-inflammatory and anti-inflammatory cytokine activities ([@bb0040]). It is a glycoprotein which consists of 184 amino acids and has a molecular weight of 26 kDa ([@bb0045]). It is involved in tumor growth, differentiation of malignant cancer cells and microenvironment immune-modulation ([@bb0080], [@bb0050]). These properties are the result of enhanced neo-angiogenesis, inhibition of cancer cell apoptosis and acquired cell resistance ([@bb0055]). IL-6 is secreted by T cells, which is capable of stimulating immune responses, including responses to tumors. The IL-6 gene is located on chromosome 7p21 and the SNPs at the 5′ flanking region of the IL-6 promoter, to be identified as IL-6 − 174 and − 572 ([@bb0060]). IL-6 (− 174) G/C genepolymorphism is one of the most frequently studied polymorphisms. IL-6 (− 174) G/C gene polymorphism alters the expression of IL-6 gene. The genotypes GC, CC and allele C of IL-6 (− 174) G/C gene polymorphism are associated with increased risk of oral cancer ([@bb0085]). Some studies observed that the IL-6 (− 174) G/C gene polymorphism was significantly associated with some cancers (breast, ovarian, prostatic, gastric, cervical and colorectal cancer) ([@bb0110], [@bb0105], [@bb0100], [@bb0095], [@bb0090]). The IL-6 (− 572) G allele is also associated with increased level of IL-6 protein in serum than C/C allele and is significantly associated with the risk of lung cancer ([@bb0115], [@bb0120]). On the contrary IL-6 (− 174 and − 572) C/G gene polymorphisms are not associated with the risk of gastric cancer, moreover they lower the risk of bladder cancer ([@bb0130], [@bb0125]).

Since the association between IL-6 (− 174G/C and − 572G/C) gene polymorphism with OSCC in the Indian population has yet not been studied, we investigated the role of IL-6 promoter (− 174) G/C and (− 572) G/C gene polymorphisms in pathogenesis of OSCC in Indian population.

Materials and methods {#s0010}
=====================

The current study was undertaken on a total of 272 OSCC patients and 185 healthy controls. Histopathologically confirmed OSCC patients from the Department of Surgical Oncology, King George\'s Medical University, UP, Lucknow were recruited for this study. Clinical information, including age, sex, tobacco chewing, smoking, alcohol consumption and TNM stages, was obtained from patients\' medical charts. This study was approved by the Institutional Ethics Committee of the King George\'s Medical University, Lucknow. An informed written consent was obtained from all the subjects.

Blood collection and molecular analyses {#s0040}
---------------------------------------

Venous blood samples were collected in EDTA tubes and stored at − 80 °C, till DNA extraction. Genomic DNA extraction from blood samples was carried out by salting out method.

Genotyping of IL-6 (− 174) G/C gene polymorphism {#s0045}
------------------------------------------------

The PCR of IL-6 (− 174) G/C, the final volume of PCR reaction mixture, was 25 μl containing 40 ng genomic DNA, 10 picomole each of forward and reverse primers (5′-TTGTCAAGACATGCCAAGTGCT-3′ and 5′-GCCTCAGAGACATCTCCAGTCC-3′) at concentration of 1X, 1X PCR master mixture. Amplification was carried out at 94 °C for 5 min followed by 35 cycles of 30 s at 94 °C for denaturation, 45 s at 57 °C for annealing, 45 s at 72 °C for extension, with a final extension at 72 °C for 7 min ([Table 1](#t0005){ref-type="table"}). An overnight digestion with 3 units *Nla*III at 37 °C yielded G allele (244 + 133 + 11) bp and C allele (133 + 111 + 56) bp products. The obtained fragments\' sizes were analyzed on a 2% agarose gel. After restriction digestion, the obtained predicted sizes of the fragments are shown in [Table 1](#t0005){ref-type="table"} and [Fig. 1](#f0005){ref-type="fig"}.

Genotyping of IL-6 (− 572) G/C gene polymorphism {#s0050}
------------------------------------------------

The PCR of IL-6 (− 572G/C), the final volume of PCR reaction mixture, was 25 μl containing 40 ng genomic DNA, 10 picomole each of forward and reverse primers (5′-GGAGACGCCTTGAAGTAACTGC-3′ and 5′-GAGTTTCCTCTGACTCCATCGCAG-3′) at concentration of 1X, 1X PCR master mixture. Amplification was carried out at 94 °C for 5 min followed by 35 cycle of 30 s at 94 °C for denaturation, 40 s at 55 °C for annealing, 30 s at 72 °C for extension, with a final extension at 72 °C for 7 min ([Table 1](#t0005){ref-type="table"}). An overnight digestion with 3 units *Mbi*I at 37 °C yielded G allele (102, 61) bp and C allele (163) bp products. The obtained fragments\' sizes were analyzed on a 2% agarose gel. After restriction digestion, the obtained predicted sizes of the fragments are shown in [Table 1](#t0005){ref-type="table"} and [Fig. 2](#f0010){ref-type="fig"}.

Statistical analysis {#s0055}
--------------------

The obtained demographics and clinical data were analyzed using Chi-square test. Genotype and allele frequencies of IL-6 were compared between OSCC cases and controls, using the Chi-square test. Odds ratios (ORs) were calculated to estimate the strength of association between the two IL-6 promoter (− 174 and − 572) gene polymorphisms and risk of OSCC. ORs are given with 95% confidence interval (CI). A '*p*-value' \< 0.05 was considered to be statistically significant.

Results {#s0015}
=======

Demographic characteristics, lifestyle and disease status of OSCC patients are previously published ([@bb0135], [@bb0140]), which included age (47.67 ± 12.67 and 43.1 ± 8.31), sexes \[(80.51% male and 76.76% male), (19.49% female and 23.24% female)\], height (162.33 ± 6.0 and 163.10 ± 5.65) and weight (55.86 ± 8.50 and 57.78 ± 7.58) in OSCC patients and controls respectively. In this study we also observed tobacco chewing (61.40%, 47.57%), smoking (30.51%, 21.62%) and alcohol consumption (13.97%, 11.35%) in OSCC patients and controls respectively. In this study we observed that smoking and tobacco chewing are significantly (*p* \< 0.05) associated, while alcohol consumption is not significantly associated with OSCC. The occurrence of tumor stages \[I (8.09%) II (56.25), III (32.72) and (1.47) IV\], tumor T status (≤ T2 71%, \> T2 29%), and lymph node status (N0 76.47% and N1 + N2 23.53%) was presented in this study.

The genotype and allele frequencies of IL-6 (− 174) G/C and (− 572) G/C {#s0020}
-----------------------------------------------------------------------

The genotype and allele frequencies of the IL-6 (− 174) G/C and IL-6 (− 572) G/C gene polymorphisms among the controls and OSCC patients are shown in [Table 2](#t0010){ref-type="table"}. The frequencies of the GG, GC and CC genotypes of IL-6 (− 174G/C) were 55.15%, 37.13% and 7.72% in the OSCC patients and 69.73%, 25.41% and 4.86% in controls, respectively. On the other hand the allele frequencies of the G and C were 73.71% and 26.29% in the OSCC patients, and 82.43% and 17.57% in controls, respectively ([Table 2](#t0010){ref-type="table"}).

There were significant differences in the GC genotype and C allele frequencies of the IL-6 (− 174) G/C gene polymorphism between OSCC patients and controls. The difference between OSCC patients and controls was statistically significant in homozygous GG and heterozygous GC genotype (OR: 1.848, CI: 1.216--2.809; *p*: 0.005) and homozygous GG and CC genotype (OR: 2.007, CI: 0.888--4.537; *p*: 0.131). C allele was also significantly increased, as compared with the G allele \[OR: 1.673, CI: 1.204 − 2.325; *p*: 0.003\] ([Table 2](#t0010){ref-type="table"}). The genotype (GG vs GC) and allele frequencies of the IL-6 (− 174) G/C gene polymorphism between control group and OSCC patients, with cancer stages (I/II and III/IV), were significantly different \[*p* = 0.0089 and 0.05 respectively\] ([Table 2](#t0010){ref-type="table"}).

The frequencies of the GG, GC and CC genotypes of IL-6 (− 572) G/C were 27.57%, 64.34% and 8.09% in the OSCC patients and 30.81%, 62.16% and 7.03% in controls, respectively. On the other hand the allele frequencies of the G and C were 59.74% and 40.26% in the OSCC patients and 59.29% and 40.71% in controls, respectively ([Table 3](#t0015){ref-type="table"}). The genotypes and allele frequencies of the IL-6 (− 572) G/C were not significantly different between controls and OSCC patients. The genotype (GG vs GC) and allele frequencies of the IL-6 (− 174) G/C gene polymorphism between controls and OSCC patients with cancer stages (I/II and III/IV), were not significantly different (*p* \> 0.05) ([Table 2](#t0010){ref-type="table"}).

Correlation between genotype distribution of IL-6 (− 174) G/C and (− 572) G/C in tobacco chewing, smoking and alcohol consumption in OSCC patients and controls {#s0025}
---------------------------------------------------------------------------------------------------------------------------------------------------------------

The correlation between genotypes and allele frequencies of IL-6 (− 174) G/C and (− 572) G/C gene polymorphisms with tobacco chewing, smoking and alcohol consumption, on OSCC susceptibility, is shown in [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}. In tobacco chewing, the genotype frequencies of GG, GC and CC of the IL-6 (− 174) G/C and (− 572) G/C gene polymorphisms were not significantly (*p* \> 0.05) associated with the development of OSCC as compared with controls ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}). However the GC genotype of the IL-6 (− 174) G/C and GC, CC genotype of the IL-6 (− 572) G/C gene polymorphism were significantly (*p* \< 0.05) associated with the development of OSCC ([Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}).

Association of IL-6 (− 174) G/C and (− 572) G/C genotypes with tumor status {#s0030}
---------------------------------------------------------------------------

We stratified the OSCC patients into two categories on the basis of disease status, *low risk OSCC group* (stage I + II, ≤ T2 and N0) and *high risk OSCC group* (stage III + IV, \> T2 and N1 + N2). Low risk OSCC group was taken as a reference. There was no significant difference between the genotype distribution of the IL-6 (− 174) G/C and (− 572) G/C gene polymorphism and tumor status (stage III + IV, \> T2 and N1 + N2), except lymph node status and GG and GC genotype of IL-6 (− 572) G/C gene polymorphism \[OR: 0.395; CI: 0.200--0.789; *p*: 0.0109\] ([Table 5](#t0025){ref-type="table"}).

Discussions {#s0035}
===========

To the best of our knowledge, this is the first study that correlates the genotype and allele frequencies of IL-6 (− 174 and − 572) gene polymorphism with OSCC, in Indian population. The immune response to inflammation frequently plays an important role in the pathogenesis of a tumor ([@bb0145]). Genetic alteration also plays a significant role in the inflammatory response, which may be associated with the risk of development of various cancers, including the oral cancer ([@bb0145]). IL-6 is an immune-regulatory cytokine with biological functions of pro-inflammation, anti-inflammation and angiogenesis. These responses are triggered by activation of the JAK tyrosine kinase family and then further stimulated by the MAPK, PI3K, or STAT signaling pathways ([@bb0155], [@bb0165], [@bb0150], [@bb0160]). It has been suggested that polymorphisms in genes, encoding inflammatory mediators, may influence the plasma level and the biological activity of the corresponding proteins ([@bb0170]). IL-6 (− 174G/C) promoter SNP is a crucial mediator of the Th2 response, that has been associated with increased IL-6 production ([@bb0145]). During the inflammation, the C allele of IL-6 (− 174) G/C gene polymorphism elevates the level of IL-6 protein ([@bb0175], [@bb0180], [@bb0105]). In addition, several studies have reported that the increased serum level of IL-6 was obtained during development and progression of tumors, including oral cancer ([@bb0105], [@bb0190], [@bb0185]). In fact, an increased level of IL-6 protein was associated with poor prognosis and high mortality in various cancers ([@bb0200], [@bb0205], [@bb0195]). [@bb0210] reported that the increased level of IL-6 was present in the serum of patients with OSCC ([@bb0210]). [@bb0165] reported that the increased expression of IL-6 in tumor cells was significantly associated with aggressive clinical manifestations and might be an independent survival predictor, particularly in male OSCC patients ([@bb0165]).

In the present study, we found that the promoter (− 174) GC genotype is significantly associated with increased risk of OSCC. Moreover, the − 174 C allele was also associated with a high risk for development of OSCC. The genotype and allele frequencies of IL-6 (− 572) G/C were not significantly associated with the risk of OSCC. Moreover these (− 174 and − 572) promoter region genotypes were not associated with the progression of OSCC. The reported observations of various studies, about the association of IL-6 gene polymorphism with various cancers, are variable. A previous study by [@bb0085] reported that the IL-6 gene polymorphism is strongly correlated with increased risk for oral cancer by affecting IL-6 gene expression. The GC heterozygotes and CC homozygotes were significantly associated with the development and progression of oral cancer ([@bb0085]). Our finding are also supported by [@bb0105] and [@bb0100], who reported that the genotypes (GC, CC) and allele C frequencies of IL-6 (− 174) G/C were significantly associated with increased risk for breast and colorectal cancers ([@bb0105], [@bb0100]). Several previous studies showed that the elevated level of IL-6 protein in serum is present in many cancers (OSCC, breast, prostate, ovarian, gastric, colorectal and cervical cancers), in which the C allele of promoter (− 174G/C) gene polymorphism was found associated with increased production of IL-6 protein and risk of cancers ([@bb0225], [@bb0110], [@bb0215], [@bb0150], [@bb0095], [@bb0220]). On the contrary, several studies reported that the IL-6 (− 174) G/C gene polymorphism was not significant associated with some cancers (breast, prostate, colorectal, lung and gastric cancer) lymphoma, melanoma and multiple myeloma ([@bb0130], [@bb0230]). [@bb0235] also did not observe any significant association between the (− 174) G/C polymorphism of IL-6 and breast cancer ([@bb0235]). Individuals with the C allele of IL-6 (− 572) G/C gene polymorphism and the GG genotype for the IL-6 (− 174) G/C gene polymorphism were associated with decreased risk of colon cancer, but with an increased risk of rectal cancer ([@bb0095]). [@bb0240] reported that the C allele at (− 572) locus of IL-6 genepolymorphism was significantly associated with lung cancer ([@bb0240]). [@bb0125] suggested that the IL-6 (− 174 C/G and − 572 C/G) gene polymorphisms were not associated with the risk of gastric cancer ([@bb0125]).

In our study the genotypes and allele frequencies of IL-6 (− 174 and − 572) G/C gene polymorphism were not associated with environmental factors (tobacco chewing, smoking and alcohol consumption) and tumor progression. These results are similar to that of [@bb0235], who showed that IL-6 (− 174) G/C gene polymorphism was not associated with either breast cancer risk or severity and prognosis, as assessed by tumor grade and lymph node status ([@bb0235]). In contrast, [@bb0085] demonstrated that the CC and GC genotypes of IL-6 (− 174) G/C polymorphism were significantly associated with the development and progression of cancer, in alcohol consuming patients. Furthermore, C allele carriers have twice as much greater relative risk for developing oral cancer in stages III & IV than in I & II ([@bb0085]). It can be concluded that the present study provides evidence of the correlation between IL-6 (− 174) G/C gene polymorphism with risk of OSCC. The GC genotype and C allele are significantly associated with the risk of OSCC, whereas IL-6 (− 572) G/C polymorphism is not associated with OSCC. Moreover related environmental factors and gene interactions are not associated with pathogenesis of OSCC. IL-6 (− 174 and − 572) promoter gene polymorphisms are not significantly associated with progression of OSCC. This finding suggests that IL-6 may be used as a diagnostic marker for effective management of OSCC in future, though further studies with larger sample sizes will be necessary to confirm this.

![PCR-RFLP analysis for IL-6 − 174G/C genotyping. The PCR-amplified product was 300 bp. The fragments after digestion with *Nla*III (lanes 1: 100 bp ladder, lanes 2, 4: GG, lanes 3, 6, 8, 9: GC and lanes 5, 7: CC genotype) were obtained.](gr1){#f0005}

![PCR-RFLP analysis for IL-6 − 572G/C genotyping. The PCR-amplified product was 163 bp. The fragments after digestion with *Mbi*I (lanes 1: 100 bp ladder, lanes 2, 3, 4, 5, 8, 9: GC, lanes 6, 10, 11: GG and lane 7: CC genotype) were obtained.](gr2){#f0010}

###### 

Primer sequences and restriction enzyme for IL-6 gene polymorphism.

  ---------------------------------------------------------------------------------------------
  SNP locus        Primer sequence                    Restriction enzyme   Product size (bp)
  ---------------- ---------------------------------- -------------------- --------------------
  IL6 (− 174G/C)   F-5′-ttgtcaagacatgccaagtgct-3′\    *Nla*III             G: 244 + 133 + 11\
                   R-5′-gcctcagagacatctccagtcc-3′                          C: 133 + 111 + 56

  IL6 (− 572G/C)   F-5′-ggagacgccttgaagtaactgc-3′\    *Mbi*I               G: 102, 61\
                   R-5′-gagtttcctctgactccatcgcag-3′                        C:163
  ---------------------------------------------------------------------------------------------

SNP, single nucleotide polymorphisms.

###### 

The genotype and allele frequencies of IL-6 (- 174 G/C and - 572 G/C) gene polymorphisms.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                    Controls      OSCC n = 272 (%)   p- Value                                 OR (95% CI)     OSCC with cancer stages I & II   p- Value                                 OR (95% CI)     OSCC with cancer stages III & IV   p- Value                                  OR (95% CI)
  ----------------- ------------- ------------------ ---------------------------------------- --------------- -------------------------------- ---------------------------------------- --------------- ---------------------------------- ----------------------------------------- ---------------
  **IL-6 (174)**                                                                                                                                                                                                                                                                     

  GG                129 (69.73)   150 (55.15)        \-                                       \-              96 (54.86)                       \-                                       \-              54 (55.67)                         \-                                        \-

  GC                47 (25.41)    101 (37.13)        0.005[⁎](#tf9005){ref-type="table-fn"}   1.848\          66 (37.72)                       0.009[⁎](#tf9005){ref-type="table-fn"}   1.887\          35 (36.08)                         0.05[⁎](#tf9005){ref-type="table-fn"}     1.779\
                                                                                              (1.216-2.809)                                                                             (1.194-2.983)                                                                                (1.036-3.055)

  CC                9 (4.86)      21 (7.72)          0.132                                    2.007\          13 (7.42)                        0.2092                                   1.941\          8 (8.25)                           0.222                                     2.123\
                                                                                              (0.888-4.537)                                                                             (0.797-4.728)                                                                                (0.778-5.796)

                                                                                                                                                                                                                                                                                     

  **Allele**                                                                                                                                                                                                                                                                         

  G                 305 (82.43)   401 (73.71)        \-                                       \-              258 (73.72)                      \-                                       \-              143 (73.72)                        \-                                        \-

  C                 65 (17.57)    143 (26.29)        0.003[⁎](#tf9005){ref-type="table-fn"}   1.673\          92 (26.28)                       0.006[⁎](#tf9005){ref-type="table-fn"}   1.673\          51 (26.28)                         0.0201[⁎](#tf9005){ref-type="table-fn"}   1.673\
                                                                                              (1.204-2.325)                                                                             (1.169-2.394)                                                                                (1.103-2.540)

                                                                                                                                                                                                                                                                                     

  **IL-6 (-572)**                                                                                                                                                                                                                                                                    

  GG                57 (30.81)    75 (27.57)         \-                                       \-              44 (25.14)                       \-                                       \-              31 (31.95)                         \-                                        \-

  GC                115 (62.16)   175 (64.34)        0.564                                    1.157\          115 (65.72)                      0.337                                    1.295\          60 (61.87)                         0.988                                     0.959\
                                                                                              (0.762-1.755)                                                                             (0.809-2.074)                                                                                (0.561-1.642)

  CC                13 (7.03)     22 (8.09)          0.6519                                   1.286\          16 (9.14)                        0.371                                    1.594\          6 (6.18)                           0.970                                     0.849\
                                                                                              (0.597-2.771)                                                                             (0.695-3.660)                                                                                (0.294-2.454)

                                                                                                                                                                                                                                                                                     

  **Allele**                                                                                                                                                                                                                                                                         

  G                 219 (59.29)   325 (59.74)        \-                                       \-              203 (58.00)                      \-                                       \-              121 (62.37)                        \-                                        \-

  C                 141 (40.71)   219 (40.26)        0.796                                    1.047\          147 (42.00)                      0.489                                    1.125\          72 (37.63)                         0.736                                     0.924\
                                                                                              (0.797-1.374)                                                                             (0.833-1.518)                                                                                (0.645-1.325)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

= Significant value

###### 

Genotype distribution of IL-6 (− 174G/C) in tobacco chewing, smoking and alcohol consumption.

                          OSCC patients   Controls       OR (95% CI)            *p*-Value
  ----------------------- --------------- -------------- ---------------------- ----------------------------------------
  *Tobacco chewing*                                                             
  Genotypes               *n* = 167 (%)   *n* = 88 (%)                          
  GG                      87 (52.10)      58 (65.91)     --                     
  GC                      67 (40.12)      25 (28.41)     0.560 (0.318--0.987)   0.051
  CC                      13 (7.78)       5 (5.68)       0.578 (0.195--1.705)   0.455
                                                                                
  *Smoking*                                                                     
  Genotypes               *n* = 83 (%)    *n* = 40 (%)                          
  GG                      47 (56.63)      30 (75.00)     --                     
  GC                      31 (37.34)      7 (17.5)       0.354 (0.138--0.905)   0.045[⁎](#tf0005){ref-type="table-fn"}
  CC                      5 (6.03)        3 (7.50)       0.940 (0.209--4.23)    0.936
                                                                                
  *Alcohol consumption*                                                         
  Genotypes               *n* = 38 (%)    *n* = 21 (%)                          
  GG                      19 (50.00)      16 (76.19)     --                     
  GC                      15 (39.47)      3 (14.29)      0.238 (0.058--0.970)   0.074
  CC                      4 (10.53)       2 (9.52)       0.594 (0.096--3.677)   0.905

Significant value.

###### 

Association between IL-6 − 572G/C genetic variations and genetic variations and tobacco chewing, smoking and alcohol consumption.

                          OSCC patients   Controls       OR (95% CI)            *p*-Value
  ----------------------- --------------- -------------- ---------------------- ----------------------------------------
  *Tobacco chewing*                                                             
  Genotypes               *n* = 167 (%)   *n* = 88 (%)                          
  GG                      41 (24.56)      30 (34.09)     --                     
  GC                      113 (67.66)     54 (61.36)     0.653 (0.369--1.157)   0.188
  CC                      13 (7.78)       4 (4.55)       0.421 (0.125--1.418)   0.251
                                                                                
  *Smoking*                                                                     
  Genotypes               *n* = 83 (%)    *n* = 40                              
  GG                      17 (20.48)      17 (42.5)      --                     
  GC                      56 (67.47)      22 (55.0)      0.421 (0.125--1.418)   0.251
  CC                      10 (12.05)      1 (2.5)        0.137 (0.017--1.127)   0.076
                                                                                
  *Alcohol consumption*                                                         
  Genotypes               *n* = 38 (%)    *n* = 21                              
  GG                      8 (21.06)       13 (61.90)     --                     
  GC                      25 (65.78)      8 (38.10)      0.197 (0.06--0.646     0.013[⁎](#tf0010){ref-type="table-fn"}
  CC                      5 (13.16)       0 (0.00)       0.057 (0.003--1.173)   0.047[⁎](#tf0010){ref-type="table-fn"}

Significant value.

###### 

IL-6 (− 174) G/C and (− 572) G/C gene polymorphisms and tumor stage, tumor T status and lymph node in OSCC patients.

  ---------------------------------------------------------------------------------------------------------
  IL-6 (− 174) G/C genotype                                                                     
  ------------------------------------- --------------- -------------- ------------------------ -----------
  Genotypes                                                                                     

   GG                                   96 (54.86)      54 (55.67)     --                       

   GC                                   66 (37.72)      35 (36.08)     0.9428 (0.5558--1.599)   0.9329

   CC                                   13 (7.42)       8 (8.25)       1.094 (0.4265--2.806)    0.8516

  Alleles                                                                                       

   G                                    258 (73.72)     143 (73.72)    --                       

   C                                    92 (26.28)      51 (26.28)     1.000 (0.6713--1.490)    0.9994

  Tumor T status                        ≤ T2\           \> T2\         OR (95% CI)              *p*-Value
                                        *n* = 193 (%)   *n* = 79 (%)                            

  Genotypes                                                                                     

   GG                                   103 (53.37)     47 (59.49)     --                       

   GC                                   76 (39.37)      25 (31.65)     0.7209 (0.4082--1.273)   0.3231

   CC                                   14 (7.26)       7 (8.86)       1.096 (0.4150--2.893)    0.8535

  Alleles                                                                                       

   G                                    282 (73.06)     119 (75.32)                             

   C                                    104 (26.94)     39 (24.68)     0.8887 (0.5804--1.361)   0.6627

  Lymph node                            N0\             N1 + N2\       OR (95% CI)              *p*-Value
                                        *n* = 205 (%)   *n* = 67 (%)                            

  Genotypes                                                                                     

   GG                                   112 (54.64)     38 (56.71)     --                       

   GC                                   79 (38.54)      22 (32.84)     0.8208 (0.4509--1.494)   0.6199

   CC                                   14 (6.82)       7 (10.45)      1.474 (0.5535--3.924)    0.6064

  Alleles                                                                                       

   G                                    303 (73.90)     98 (73.13)     --                       

   C                                    107 (26.10)     36 (26.87)     1.040 (0.6692--1.617)    0.9503

                                                                                                

  Il-6 (− 572) G/C gene polymorphisms                                                           

                                                                                                

                                        I + II\         III + IV\      OR (95% CI)              *p*-Value
                                        *n* = 175 (%)   *n* = 97 (%)                            

                                                                                                

  Genotypes                                                                                     

   GG                                   44 (25.14)      31 (31.95)     --                       

   GC                                   115 (65.72)     60 (61.87)     0.7405 (0.4248--1.291)   0.3587

   CC                                   16 (9.14)       6 (6.18)       0.5323 (0.1872--1.513)   0.3450

  Alleles                                                                                       

   G                                    203 (58.00)     121 (62.37)    --                       

   C                                    147 (42.00)     72 (37.63)     0.8217 (0.5728--1.179)   0.3291

  Tumor T status                        ≤ T2\           \> T2\         OR (95% CI)              *p*-Value
                                        *n* = 193 (%)   *n* = 79 (%)                            

  Genotypes                                                                                     

   GG                                   50 (25.91)      25 (31.65)     --                       

   GC                                   126 (65.28)     49 (62.03)     0.7778 (0.4343--1.393)   0.4868

   CC                                   17 (8.81)       5 (6.32)       0.5882 (0.1944--1.779)   0.4939

  Alleles                                                                                       

   G                                    226 (58.55)     99 (62.66)     --                       

   C                                    160 (41.45)     59 (37.34)     0.8418 (0.5752--1.232)   0.4290

  Lymph node status                     N0\             N1 + N2\       OR (95% CI)              *p*-Value
                                        *n* = 205 (%)   *n* = 67 (%)                            

  Genotypes                                                                                     

   GG                                   55 (26.83)      20 (29.85)     --                       

   GC                                   133 (64.88)     42 (62.69)     0.8684 (0.4679--1.612)   0.7736

   CC                                   17 (8.29)       5 (7.46)       0.8088 (0.2636--2.482)   0.9249

  Alleles                                                                                       

   G                                    243 (59.27)     82 (61.19)     --                       

   C                                    167 (40.73)     52 (38.81)     0.9227 (0.6188--1.376)   0.7694
  ---------------------------------------------------------------------------------------------------------
